Monday, June 30, 2008

Alzheimer's Drug problems

According to Ed Silverman in his Pharmalot blog, Myriad Genetics is discontinuing development of Flurizan, their Alzheimer's drug. But there is a bigger issue at stake here than just the failure of one drug. As Ed writes in his blog:

The failure is significant because Flurizan was one of the first drugs to reach late-stage testing that tried to prevent the buildup of amyloid plaque in the brain, a focus of much research into Alzheimer’s. Whether this will raise questions about other drugs targeting amyloid plaque remains to be seen.

Wyeth and Elan are jointly developing a drug that tries to block amyloid plaque and, so far, have generated considerable interest, even though preliminary Phase II results were mixed. Lilly is also in late-stage testing of a drug that works simlarly to Flurizan

Bottom line....are all these companies chasing after the wrong cure for Alzheimer's?

Saturday, June 28, 2008

Pharma and the UK

According to an article in Thursday's Financial Times
Leading pharmaceutical groups are cutting back on clinical research in the UK, claiming insufficient commitment by the government and the National Health Service to support new drug development.

Pfizer of the US, Roche of Switzerland and Merck-Serono of Germany are among the companies which have told the Financial Times they have, or will, reduce the number of British patients enrolled in trials to test experimental medicines for life-threatening diseases such as cancer.

The article goes on the quote Harpal Kumar, who is the head of Cancer Research UK, who said:

“In the long-term there is a serious risk that if we get to the point where none of the new drugs are being used in the UK, the trials won’t be done here.”


There are many issues that can be addressed concerning the ongoing debate between the Government in the UK and the Pharma industry over the issues of costs. But the overriding issue here is that people in the UK will ultimately be denied access to new innovative drug treatments. Innovative treatments that save lives will be available in the future, but for people in the UK, they will not have the option of using them. That is a crime.

Thursday, June 05, 2008

Novartis CEO - "Teva is better than we are."

File this quote under the category of 'Things you don't hear every day".
In a recent interview, Novartis CEO Dan Vasella said:

“Teva is better than we are, and that’s hard to take."

But Vasella did add:

“It is good to look at how we could be better.”

How often do you hear a CEO so openly praising the competition?
How often do you hear a CEO so openly criticizing his own organization?

Wednesday, June 04, 2008

War for Talent impacts the FDA

According to this article in the Hartford Courant, even the FDA is not immune to the effects of the War for Talent. Private sector Pharmaceutical companies have been poaching talent from the FDA, and it looks like there is no end in sight for the 'Brain Drain' at the Agency.